Tempus has built the world’s largest library of clinical & molecular data and an operating system to make that data accessible and useful, starting with cancer.
Tempus Hub provides a secure platform for managing your Tempus-related activities and information.
Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, [5] for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on , under the ticker symbol "TEM." [6][7]
Should You Buy or Sell Tempus AI Stock? Get The Latest TEM Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat.
Complete Tempus AI Inc. stock information by Barron's. View real-time TEM stock price and news, along with industry-best analysis.
Join Tempus and help advance precision medicine. Explore open roles in engineering, research, clinical operations, and more to build the future of healthcare.
Tempus is a healthcare technology company advancing the use of AI in precision oncology. By integrating comprehensive molecular and clinical data, we deliver actionable insights that help oncologists make more informed decisions throughout the patient journey.
For clinicians associated with advanced research initiatives, Tempus provides next-generation genomic profiling, biological organoid modeling, image/pattern AI recognition, and a range of clinical trial and research collaborations.
At Tempus, we are changing the way precision oncology care is delivered. By leveraging the power of clinical and molecular data, we offer comprehensive genomic profiling services that are reshaping the way cancer is diagnosed and treated.
Business Wire: Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...